eFFECTOR Therapeutics, Inc.
EFTR evidence brief
What we can confirm
- Market Cap:
- $940
What it means
What to watch
Prepared research question
What matters most for EFTR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$940
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Run eFFECTOR Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available eFFECTOR Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Financials
Short Interest
as of Apr 29, 2026- % of float
- 2.0%
- Days to cover
- 1.0
- Shares short
- 91,617
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EFTR short interestGovernance
Frequently asked questions
Who is the CEO of eFFECTOR Therapeutics, Inc.?
Stephen T. Worland, Ph.D. is the chief executive officer of eFFECTOR Therapeutics, Inc. (EFTR).
Where is eFFECTOR Therapeutics, Inc. headquartered?
eFFECTOR Therapeutics, Inc. (EFTR) is headquartered in Solana Beach, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.